sal next-generation sequencing (NGS)-based oncology test system. In September 2014, Sanofi and MyoKardia, Inc. announced a worldwide collaboration to discover and develop first-of-its-kind targeted therapeutics for heritable heart diseases known as cardiomyopathies, the most common forms of heart muscle disease. In September 2014, MannKind Corporation announced the closing of a worldwide exclusive collaboration and licensing agreement with Sanofi for development and commercialization of Afrezza(R) (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes. In September 2014, Apollo Hospitals and Sanofi announced their decision to collaborate on the expansion of Apollo Sugar Clinics, which provide integrated diabetes care programs in India. Through this collaboration, Apollo and Sanofi plan to leverage their respective expertise in diabetes to provide patients with access to comprehensive educational resources, treatment and care programs that can help patients better manage their diabetes. In October 2014, Selecta Biosciences, Inc., and JDRF, announced that they have extended their joint research collaboration and attracted Sanofi as a partner in support of their program to develop a Synthetic Vaccine Particle (SVP) immunotherapy with the long-term goal to treat and potentially prevent the underlying cause of type 1 diabetes. In November 2014, Sanofi has signed a co-operation healthcare agreement with the Galician Healthcare Service (SERGAS) in Spain. In November 2014, Evotec AG announced that it has entered into exclusive negotiations with Sanofi on a major multi-component strategic alliance over the next five years. In December 2014, Sanofi announced the opening of its production facility in King Abdullah Economic City's (KAEC) Industrial Valley. In January 2015, VECT-HORUS announced the signing of a scientific collaboration agreement with SANOFI. In February 2015, Adimab has signed a multi-target discovery and optimisation collaboration with Sanofi. Part of the deal will see Adimab will use its proprietary platform to produce therapeutic antibodies and bispecifics molecules against multiple targets, which will be developed and commercialised by Sanofi. In February 2015, Sanofi announced a research collaboration and license agreement with Lead Pharma to discover, develop and commercialize small-molecule therapies directed against the nuclear hormone receptors called ROR gamma to treat a broad range of autoimmune disorders, including rheumatoid arthritis, psoriasis and inflammatory bowel disease. History The company was founded in 1970. It was formerly known as Sanofi-Aventis and changed its name to Sanofi in 2011.
sanofi-titr part10%87 (RHPP:EN Paris)
54, Rue La Boétie
Phone: 33 1 53 77 40 00
|Amgen Inc||$157.72 USD||-1.25|
|Bayer AG||€131.62 EUR||+0.108|
|Celgene Corp||$121.53 USD||-1.82|
|Gilead Sciences Inc||$103.53 USD||-0.66|
|Novo Nordisk A/S||kr319.70 DKK||+3.70|
|View Industry Companies|
Sponsored Financial Commentaries
To contact SANOFI-TITR PART10%87, please visit www.sanofi.com. Company data is provided by Capital IQ. Please use this form to report any data issues.